Debut at BIOCHINA 2026: iMBioRay's Off-the-Shelf NK Cells Show Industry-Leading Strength

On March 12, BIOCHINA 2026 (11th edition), the CBMG BioIndustry Expo, opened in Suzhou, where global think tanks gathered to explore trends in biopharmaceuticals. At this high-profile event, iMBioRay made a major appearance with its core NK cell technologies and forward-looking R&D roadmap. With strong technological barriers and clinical translation achievements, iMBioRay became one of the highlights of the exhibition.

A Decade of Deep Cultivation: Pioneering an Innovative Path for NK Cell Therapy

At the exhibition, iMBioRay not only showcased cutting-edge achievements but was invited to deliver two professional, forward-looking talks. The core breakthroughs, clinical research progress and future paradigm of iMBioRay's off-the-shelf NK cell therapy drew great attention and lively discussion.

Dr. Miao Zhenwei, Chairman and CEO of iMBioRay, delivered a keynote titled "Clinical Research of Antibody NK Cell Conjugate (ACC NK) in Cancer Therapy." Focusing on global pain points in oncology, he interpreted the R&D logic, mechanism of action and clinical progress of ACC NK, a disruptive cell therapy.

Dr. Miao noted that traditional NK cell therapy still has room to improve in tumor targeting and killing efficiency. Antibody NK Cell Conjugate (ACC NK) innovatively combines the precise targeting of antibodies with the natural killing activity of NK cells, achieving dual breakthroughs in precise positioning and efficient killing. It can accurately identify tumor cell targets, greatly improve treatment safety and efficacy, and shows strong clinical potential, especially in solid tumor therapy.

Dr. He Xiangfeng, Chief Medical Officer of iMBioRay, gave a talk titled "iMBioRay's Off-the-Shelf NK Cells and New Paradigms for Disease Treatment." Focusing on the demand for inclusive, large-scale development in cell therapy, he explained the technological advantages, clinical application scenarios and industry-transformation value of off-the-shelf NK cells.

Dr. He stated that current autologous cell therapy faces problems such as long preparation cycles, poor quality of patients' own immune cells and high treatment costs, making large-scale clinical adoption difficult. Off-the-shelf NK cells are the core solution to this dilemma. Independently developed by iMBioRay, they rely on a standardized GMP production system to achieve large-scale expansion, immune-trained culture and standardized preparation of healthy donor cells, enabling ready-to-use therapy that balances efficacy and clinical convenience. Dr. He shared iMBioRay's progress applying off-the-shelf NK cells in autoimmune diseases and other fields with clinical cases, and proposed a new treatment paradigm of off-the-shelf supply, immediate treatment and universal accessibility, which rewrites the traditional application logic of cell therapy.

Empowered by Cutting-Edge Technology: Core Competitive Advantages

Amid increasingly fierce competition in cell therapy, iMBioRay stands out thanks to technological originality, advancement and clinical implementation. Compared with similar products, it has formed several irreplaceable core advantages.

Strong technological originality, breaking industry bottlenecks: iMBioRay's independently developed ACC NK antibody-cell conjugation is a world-leading original technology. It integrates antibody targeting with NK cell killing, solving the industry problems of insufficient targeting and poor solid-tumor penetration of traditional NK cells, with excellent clinical data and strong technological barriers.

Outstanding clinical value, wide indication coverage: Supported by these advantages, off-the-shelf NK cells show prominent clinical value. In trials they show significant effects on hematologic tumors such as leukemia and lymphoma, and achieve breakthroughs in solid tumors including lung, liver and breast cancer. They can also extend to autoimmune and neurodegenerative diseases and other fields, covering a wide range of indications. Products in clinical research have shown high safety, low adverse-reaction rates and good tolerance, with strong translation value.

Leading industrialization capability, inclusive implementation: iMBioRay has built a GMP production workshop and completed four technology iterations, achieving large-scale, modular, fully closed and automated NK cell expansion and culture. It has established a 300-liter ultra-large-capacity system, with a single batch supporting 200 treatment courses, greatly reducing production costs. This moves cell therapy from a niche high-end therapy toward a mass inclusive therapy, bringing cutting-edge cell therapy to more ordinary patients.

Anchoring Cutting-Edge Innovation: Leading the New Future of Cell Therapy

The cell therapy industry is at a critical juncture from technological innovation to clinical inclusiveness. Guided by the philosophy that "the light of immunotherapy lights up new hope for life," iMBioRay focuses on a series of off-the-shelf NK cell therapy products including ACC NK, tiNK and ATE NK. It continues to deepen cutting-edge R&D, accelerate its clinical pipeline and product commercialization, and is committed to building a world-leading NK cell therapy innovation platform.

Going forward, iMBioRay will rely on its top R&D team and core technological advantages, link upstream and downstream industrial resources, deepen clinical cooperation and industrial collaboration, promote the clinical translation of more cutting-edge cell therapies, and bring more efficient, safer and more accessible treatment solutions to patients worldwide.